Krystal Biotech, Inc. (KRYS)

NASDAQ: KRYS · IEX Real-Time Price · USD
162.83
-0.79 (-0.48%)
May 24, 2024, 4:00 PM EDT - Market closed
-0.48%
Market Cap 4.65B
Revenue (ttm) 95.95M
Net Income (ttm) 57.16M
Shares Out 28.56M
EPS (ttm) 1.88
PE Ratio 86.61
Forward PE 61.13
Dividend n/a
Ex-Dividend Date n/a
Volume 143,532
Open 163.92
Previous Close 163.62
Day's Range 162.83 - 162.83
52-Week Range 93.95 - 189.97
Beta 0.90
Analysts Strong Buy
Price Target 172.10 (+5.69%)
Earnings Date May 6, 2024

About KRYS

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cys... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 229
Stock Exchange NASDAQ
Ticker Symbol KRYS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for KRYS stock is "Strong Buy." The 12-month stock price forecast is $172.1, which is an increase of 5.69% from the latest price.

Price Target
$172.1
(5.69% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new pre...

12 days ago - GlobeNewsWire

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

PITTSBURGH, May 08, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the B...

19 days ago - GlobeNewsWire

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

Net product revenue of $45.3 million in 1Q and $95.9 million since August First patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lung Received Fast Track Designati...

21 days ago - GlobeNewsWire

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new pre...

25 days ago - GlobeNewsWire

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 202...

4 weeks ago - GlobeNewsWire

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

• Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biote...

5 weeks ago - GlobeNewsWire

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanced local and systemic effector T-cell responses in cold tumor preclinical model Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanc...

7 weeks ago - GlobeNewsWire

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the T...

3 months ago - GlobeNewsWire

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

•  Net product revenue of $42.1M in 4Q and $50.7M for the year •  New England Journal of Medicine publication of the use of B-VEC eyedrop formulation •  Reached alignment with FDA to enable approval o...

3 months ago - GlobeNewsWire

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023 financia...

3 months ago - GlobeNewsWire

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

• FDA clears IND and Phase 1 (KYANITE-1) clinical trial expected to be initiated in 1H 2024 PITTSBURGH, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commer...

3 months ago - GlobeNewsWire

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

• Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional applications of Krystal's HSV-1 platform to treat ocular diseases

3 months ago - GlobeNewsWire

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

PITTSBURGH, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the G...

4 months ago - GlobeNewsWire

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

PITTSBURGH, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization...

5 months ago - GlobeNewsWire

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

PITTSBURGH, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization...

5 months ago - GlobeNewsWire

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

PITTSBURGH, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization...

6 months ago - GlobeNewsWire

Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

PITTSBURGH, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization...

7 months ago - GlobeNewsWire

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

•   284 VYJUVEK Patient Start Forms and $8.6 million in VYJUVEK U.S. net product revenue as of the end of the third quarter •   Cohort 1 completed in Phase 1 clinical trial of KB407 for the treatment ...

7 months ago - GlobeNewsWire

Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

PITTSBURGH, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization...

7 months ago - GlobeNewsWire

Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

PITTSBURGH, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercializatio...

8 months ago - GlobeNewsWire

Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

• Orphan Drug Designation Granted to KB408 PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the ...

8 months ago - GlobeNewsWire

Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

PITTSBURGH, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercializatio...

9 months ago - GlobeNewsWire

Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

PITTSBURGH, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercializatio...

9 months ago - GlobeNewsWire

Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million

PITTSBURGH, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), a commercial-stage biotechnology company focused on the discovery, development, and commercializatio...

10 months ago - GlobeNewsWire

Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights

• VYJUVEK™ approved in the U.S. as the first and only topical redosable gene therapy for the treatment of dystrophic epidermolysis bullosa

10 months ago - GlobeNewsWire